A phase Ib/II study of cancer sternness inhibitor napabucasin (BBI-608) in combination with gemcitabine (gem) and nab-paclitaxel (nabPTX) in metastatic pancreatic adenocarcinoma (mPDAC) patients (pts).

被引：14
|
作者：
Bekaii-Saab, Tanios S.
Starodub, Alexander
El-Rayes, Bassel F.
O'Neil, Bert H.
Shanda, Safi
Ciombor, Kristen Keon
Noonan, Anne M.
Hanna, Wahid Tewfik
Sehdev, Amikar
Shaib, Walid Labib
Mikhail, Sameh
Neki, Anterpreet S.
Oh, Cindy
Li, Youzhi
Li, Wei
Borodyansky, Laura
Li, Chiang
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.4106
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4106
引用
收藏
页数：5
相关论文
共 50 条
  • [31] Phase I study of nab-paclitaxel and gemcitabine combination in patients with advanced pancreatic cancer
    Drengler, R. L.
    Smith, L. S.
    Wood, T. E.
    Borad, M. J.
    Ramanathan, R. K.
    Laheru, D. A.
    Hidalgo, M.
    Von Hoff, D. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [32] Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma
    De Jesus-Acosta, Ana
    Sugar, Elizabeth A.
    O'Dwyer, Peter J.
    Ramanathan, Ramesh K.
    Von Hoff, Daniel D.
    Rasheed, Zeshaan
    Zheng, Lei
    Begum, Asma
    Anders, Robert
    Maitra, Anirban
    McAllister, Florencia
    Rajeshkumar, N. V.
    Yabuuchi, Shinichi
    de Wilde, Roeland F.
    Batukbhai, Bhavina
    Sahin, Ismet
    Laheru, Daniel A.
    BRITISH JOURNAL OF CANCER, 2020, 122 (04) : 498 - 505
  • [33] Phase I/II study of LDE225 in combination with gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer.
    Pijnappel, Esther N.
    Wassenaar, Nienke P. M.
    Gurney-Champion, Oliver J.
    Klaassen, Remy
    van der Lee, Koen S.
    Pleunis-van Empel, Marjolein
    Richel, Dick J.
    Legdeur, Marie-Cecile J. C.
    Nederveen, Aart J.
    Van Laarhoven, Hanneke W. M.
    Wilmink, Johanna
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [34] A phase II study of vismodegib, a hedgehog (Hh) pathway inhibitor, combined with gemcitabine and nab-paclitaxel (nab-P) in patients (pts) with untreated metastatic pancreatic ductal adenocarcinoma (PDA)
    De Jesus-Acosta, Ana
    O'Dwyer, Peter J.
    Ramanathan, Ramesh K.
    Von Hoff, Daniel D.
    Maitra, Anirban
    Rasheed, Zeshaan
    Zheng, Lei
    Rajeshkumar, N. V.
    Le, Dung T.
    Hoering, Antje
    Bolejack, Vanessa
    Yabuuchi, Shinichi
    Laheru, Daniel A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [35] Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma
    Ana De Jesus-Acosta
    Elizabeth A. Sugar
    Peter J. O’Dwyer
    Ramesh K. Ramanathan
    Daniel D. Von Hoff
    Zeshaan Rasheed
    Lei Zheng
    Asma Begum
    Robert Anders
    Anirban Maitra
    Florencia McAllister
    N. V. Rajeshkumar
    Shinichi Yabuuchi
    Roeland F. de Wilde
    Bhavina Batukbhai
    Ismet Sahin
    Daniel A. Laheru
    British Journal of Cancer, 2020, 122 : 498 - 505
  • [36] Phase III study of nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem alone in patients (pts) with metastatic pancreatic adenocarcinoma (mPC): Subgroup analysis of Canadian pts from the MPACT trial
    Tehfe, Mustapha Ali
    Dowden, Scot D.
    Kennecke, Hagen F.
    El-Maraghi, Robert Hassan
    Lesperance, Bernard
    Couture, Felix
    Letourneau, Richard
    Penenberg, Darryl Neil
    Romano, Alfredo
    Von Hoff, Daniel D.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [37] Preliminary results of a phase II study of surufatinib plus sintilimab, nab-paclitaxel and gemcitabine (AG) as first-line therapy in patients (pts) with locally advanced or metastatic pancreatic adenocarcinoma (mPDAC).
    Zhang, Dong-Sheng
    Liu, Fu-Rong
    Lu, Yun-Xin
    Bai, Bing
    Zhang, Yang
    Wang, Zhi-Qiang
    Liu, Yu
    Chen, Jian-Wen
    Wang, Feng
    Xu, Rui-Hua
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 659 - 659
  • [38] Phase 1 trial of gemcitabine/nab-paclitaxel in combination with the autophagy inhibitor hydroxychloroquine in previously untreated patients with metastatic pancreatic adenocarcinoma.
    O'Hara, Mark H.
    Gallagher, Maryann
    Teitelbaum, Ursina R.
    Giantonio, Bruce J.
    Damjanov, Nevena
    Loaiza-Bonilla, Arturo
    Amaravadi, Ravi K.
    Heitjan, Daniel F.
    Vasilevskaya, Irina
    Von Hoff, Daniel D.
    Ramanathan, Ramesh K.
    Laheru, Dan
    De Jesus-Acosta, Ana
    Velculescu, Victor E.
    O'Dwyer, Peter J.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [39] Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trial
    Bekaii-Saab, Tanios
    Okusaka, Takuji
    Goldstein, David
    Oh, Do-Youn
    Ueno, Makoto
    Ioka, Tatsuya
    Fang, Weijia
    Anderson, Eric C.
    Noel, Marcus S.
    Reni, Michele
    Choi, Hye Jin
    Goldberg, Jonathan S.
    Oh, Sang Cheul
    Li, Chung-Pin
    Tabernero, Josep
    Li, Jian
    Foos, Emma
    Oh, Cindy
    Van Cutsem, Eric
    ECLINICALMEDICINE, 2023, 58
  • [40] A phase Ib study evaluating olaratumab in combination with nab-paclitaxel and gemcitabine in first-line treatment of metastatic pancreatic cancer.
    Pelzer, Uwe
    Bendell, Johanna C.
    Womack, Mark S.
    Bahary, Nathan
    Macarulla, Teresa
    Borazanci, Erkut Hasan
    Levy, Donna Elise
    Mo, Gary
    Ramage, Samuel Cowan
    Garrido-Laguna, Ignacio
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
12345